EYPT—(+176%)—reports phase-2 non-inferiority of AMD drug-eluting implant to (regular-dose) Eylea: https://www.globenewswire.com/news-release/2023/12/04/2789884/0/en/EyePoint-Pharmaceuticals-Announces-Positive-Topline-Data-from-the-Phase-2-DAVIO-2-Trial-of-EYP-1901-in-Wet-AMD-Achieving-All-Primary-and-Secondary-Endpoints.html